Antag Therapeutics Announces €80 Million Series A Financing

-- Round led by Versant Ventures with participation from founding investor Novo Holdings and new investors SR One, Dawn Biopharma and Pictet-- --Entering Phase I testing for next-generation weight loss therapy by antagonizing GIPR-- COPENHAGEN, Denmark, Dec. 4, 2024 /PRNewswire/ -- Antag...